Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Kenji Tanabe, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Tanabe and John Mullen.
Connection Strength

1.581
  1. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer. 2004 Aug 15; 101(4):869-77.
    View in: PubMed
    Score: 0.293
  2. Viral oncolysis for malignant liver tumors. Ann Surg Oncol. 2003 Jul; 10(6):596-605.
    View in: PubMed
    Score: 0.271
  3. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg. 2002 Oct; 236(4):502-12; discussion 512-3.
    View in: PubMed
    Score: 0.258
  4. Viral oncolysis. Oncologist. 2002; 7(2):106-19.
    View in: PubMed
    Score: 0.245
  5. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 2004 Apr 01; 64(7):2561-7.
    View in: PubMed
    Score: 0.071
  6. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer. 2002 Sep 01; 95(5):1171-81.
    View in: PubMed
    Score: 0.064
  7. Viral oncolysis. Surg Oncol Clin N Am. 2002 Jul; 11(3):661-80.
    View in: PubMed
    Score: 0.063
  8. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest. 2002 Apr; 109(7):871-82.
    View in: PubMed
    Score: 0.062
  9. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 2001 Jul 15; 61(14):5447-52.
    View in: PubMed
    Score: 0.059
  10. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. 2000 Jun 01; 60(11):2790-5.
    View in: PubMed
    Score: 0.055
  11. Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery. JAMA Surg. 2020 02 01; 155(2):123-129.
    View in: PubMed
    Score: 0.054
  12. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  13. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.